Praziquantel

Spezifikationen

55268-74-1CAS-Nummer

259-559-6EG-Nummer

2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-oneIUPAC-Name

C19H24N2O2Chemische Formel

312.4 g/molMolekulargewicht

praziquantel; 55268-74-1; Biltricide; Droncit; Embay 8440; Praziquantelum; Cysticide; DTXSID9021182; 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; prazicuantel; EMBAY-8440; NSC-757285; 4H-Pyrazino(2,1-a)isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; DTXCID501182; Prasiquantel; 6490C9U457; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino[2,1-a]isoquinolin-4-one; BROADLINE COMPONENT PRAZIQUANTEL; PROFENDER COMPONENT PRAZIQUANTEL; Cisticid; 4H-Pyrazino[2,1-a]isoquinolin-4-one, 2-(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-; Cestocur; Prazitech; PraziCleanse; GiarCidia Prazi; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-piperazino(2,1-a)isoquinolin-4-one; Praziquantel Tablets; DACTYMOR; Praziquantel Injection; RefChem:55908; Droncit Canine Cestocide; Droncit Feline Cestocide; Durvet Feline Tape Tabs; Tapeworm Dewormer for Cats; CHEBI:45267; P02BA01; TAPEWORM DEWORMER FOR DOGS; Durvet Feline Tape Tabs for Cats; Droncit 5.68% Injectible Solution; Worm and Parasites Aquarium Cure Program Salt; Worm and Parasites Aquarium Cure Program Fresh; Prazi-C Tablets (OTC), Praziquantel Tablets (Rx); 259-559-6; Droncit Canine Cestocide Tablets, Droncit Feline Cestocide Tablets, Praziquantel 34 (Rx), Tapeworm Dewormer for Cats (OTC), Tapeworm Dewormer for Dogs (OTC); Pyquiton; Cesol; Azinox; 2-(cyclohexanecarbonyl)-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; Praziquantel (Biltricide); MFCD00058531; 2-(cyclohexanecarbonyl)-2,3,6,7-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4(11bH)-one; MLS000038419; SMR000037139; Cutter Tape Tabs; 2-(cyclohexanecarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one; Distocide; Prazinon; d-Praziquantel; Praziquantelum [INN-Latin]; (+/-)-Praziquantel; Cutter; 2-cyclohexanecarbonyl-1H,2H,3H,4H,6H,7H,11bH-pyrazino[2,1-a]isoquinolin-4-one; Biltricide (TN); CCRIS 4114; SR-01000003100; EINECS 259-559-6; 135526-78-2; BRN 0761557; Bay-8440; Praziquantel (JAN/USP/INN); UNII-6490C9U457; NCGC00016877-01; Prestwick_402; CAS-55268-74-1; Praziquantel [USAN:USP:INN:BAN:JAN]; Spectrum_001119; Praziquantel (Standard); Opera_ID_378; Prestwick0_000260; Prestwick1_000260; Prestwick2_000260; Prestwick3_000260; Spectrum2_001288; Spectrum3_000550; Spectrum4_000482; Spectrum5_001064; PRAZIQUANTEL [MI]; PRAZIQUANTEL [INN]; PRAZIQUANTEL [JAN]; CHEMBL976; P 4668; PRAZIQUANTEL [USAN]; cid_4891; PRAZIQUANTEL [VANDF]; Lopac0_000909; Oprea1_163497; SCHEMBL44153; BSPBio_000080; BSPBio_002199; KBioGR_000963; KBioSS_001599; PRAZIQUANTEL [MART.]; 5-24-03-00361 (Beilstein Handbook Reference); MLS000028528; MLS001201812; MLS001304085; MLS002548849; MLS006011880; DivK1c_000130; PRAZIQUANTEL [USP-RS]; PRAZIQUANTEL [WHO-DD]; PRAZIQUANTEL [WHO-IP]; SPECTRUM1500494; SPBio_001295; SPBio_002299; BPBio1_000088; orb1308625; orb3025180; SCHEMBL16019896; BDBM74574; CHEBI:91583; HMS500G12; HY-B0244R; KBio1_000130; KBio2_001599; KBio2_004167; KBio2_006735; KBio3_001699; PRAZIQUANTEL [GREEN BOOK]; NINDS_000130; GLXC-07070; GLXC-26256; HMS1568D22; HMS1920J06; HMS2090J19; HMS2092A09; HMS2095D22; HMS3259K07; HMS3262F20; HMS3655O19; HMS3712D22; HMS5079N12; Pharmakon1600-01500494; PRAZIQUANTEL [ORANGE BOOK]; PRAZIQUANTEL [EP MONOGRAPH]; PRAZIQUANTEL [USP IMPURITY]; HY-B0244; MSK20471; PRAZIQUANTEL [USP MONOGRAPH]; Tox21_110660; Tox21_201950; Tox21_302927; Tox21_500909; CCG-39773; EBC-11170; NSC757285; Praziquantel, anthelminic, neurogenic; s1691; STK030186; PRAZIQUANTELUM [WHO-IP LATIN]; AKOS000541869; AKOS016398525; Tox21_110660_1; AC-8426; DB01058; FP27126; LP00909; NC00468; NSC 757285; SB49202; SDCCGSBI-0050884.P005; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazinoe(2,1a)isoquinolin-4-one; IDI1_000130; NCGC00015818-04; NCGC00015818-05; NCGC00015818-06; NCGC00015818-07; NCGC00015818-08; NCGC00015818-11; NCGC00015818-12; NCGC00015818-14; NCGC00015818-15; NCGC00015818-24; NCGC00015818-26; NCGC00089733-02; NCGC00089733-03; NCGC00089733-04; NCGC00089733-05; NCGC00256422-01; NCGC00259499-01; NCGC00261594-01; AS-12459; SY052322; SBI-0050884.P004; DB-052707; PRAZIQUANTEL (EMA EPAR: VETERINARY); AB00052075; EU-0100909; NS00010534; P2125; P7103; ST50904686; SW196645-3; C07367; D00471; EN300-123768; AB00052075-13; AB00052075-15; AB00052075_16; AB00052075_17; Praziquantel, VETRANAL(TM), analytical standard; F358136; Q424145; SR-01000003100-3; SR-01000003100-5; SR-01000003100-7; BRD-A21858158-001-05-2; BRD-A21858158-001-16-9; BRD-A21858158-001-22-7; BRD-A21858158-001-23-5; SR-01000003100-16; F0037-0136; Z1554103331; Praziquantel, European Pharmacopoeia (EP) Reference Standard; Praziquantel, United States Pharmacopeia (USP) Reference Standard; 10-(cyclohexylcarbonyl)-5,6,7,11a-tetrahydropiperazino[2,1-a]isoquinolin-8-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro- 4H-pyrazino[2,1-a]-isoquinolin-4-one; 2-(Cyclohexylcarbonyl)-1,2,3,6,7-11b-hexahydro-4H-pyrazino[2,1-aisoquinolin-4-one; 2-[cyclohexyl(oxo)methyl]-3,6,7,11b-tetrahydro-1H-pyrazino[2,1-a]isoquinolin-4-one; 2-Cyclohexylcarbonyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino(2,1-a)isoquinolin-4-one; Praziquantel for system suitability, European Pharmacopoeia (EP) Reference Standard; Praziquantel, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C19H24N2O2/c22-18-13-20(19(23)15-7-2-1-3-8-15)12-17-16-9-5-4-6-14(16)10-11-21(17)18/h4-6,9,15,17H,1-3,7-8,10-13HSynonyme